Viatris Inc VIA

XET: VIA | ISIN: US92556V1061   17/05/2024
10,13 EUR (-1,46%)
(-1,46%)   17/05/2024

9 mei 2024 · Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges · Persbericht

2 mei 2024 · Viatris to Participate in the BofA Securities 2024 Health Care Conference · Persbericht

1 mei 2024 · Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health · Persbericht

16 april 2024 · Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 · Persbericht

15 april 2024 · Viatris Appoints Corinne Le Goff as Chief Commercial Officer · Persbericht

1 april 2024 · Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States · Persbericht

27 maart 2024 · Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline · Persbericht

28 februari 2024 · Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance · Persbericht

28 februari 2024 · Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration · Persbericht

5 februari 2024 · Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results · Persbericht

21 december 2023 · Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

15 december 2023 · Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer · Persbericht

15 december 2023 · Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders · Persbericht

13 november 2023 · Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) · Persbericht

7 november 2023 · Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] · Persbericht

30 oktober 2023 · Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance · Persbericht

23 oktober 2023 · Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row · Persbericht

20 oktober 2023 · Rajiv Malik to Retire as President of Viatris Effective April 1, 2024 · Persbericht

18 oktober 2023 · Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking · Persbericht

10 oktober 2023 · Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023 · Persbericht

Mijn selecties